Company UpdateEarnings Call Transcript
Zim Laboratories Q1 FY27: EU-GMP remediation progresses; exports share high; FY28 growth hinging on regulatory clearance.
Financial Performance
- Total operating income: INR 942 million, up 31.2% YoY.
- EBITDA: INR 34 million; margin 3.7%.
- PAT: negative INR 40 million vs negative INR 19 million prior year.
- Exports ~84% of total income; NIP/OTF ~18%.
- Gross margin ~58% in Q1; Q1 one-time costs: TGA audit 0.30 crore; MIDC 1.9 crore.
- Debt: INR 145.2 crore; R&D spend: INR 8.2 crore.
EU-GMP Progress
- EU-GMP inspection completed; final report awaited; CAPA plan prepared.
- Draft observations shared; no critical observations; CAPA to be submitted after final report.
- Regulatory remediation investments; positioned for growth in regulated markets.
Outlook and Guidance
- FY27 is a transition year; EU-GMP progress crucial.
- FY28 growth target: 30-40% if EU-GMP enables supplies.
- Without EU-GMP, FY27 growth 10-15%; margins near last year.
- Capex largely complete; INR 15-20 crore for enzyme and Nutra upgrades.
- MA for 8-10 products post-EU-GMP; Q4 revenue possible.
Q&A Highlights
- Q1 momentum described as among best in years; EU-GMP timing remains key.
- Q1 costs include AUD TGA and MIDC charges; not recurring.
- Debtors days around 100; target reduction to 80 days.
- Australia TGA CAPA submitted; certificate due in coming months; first order underway.
- Two quarters after CAPA, MA approvals; potential Q4 revenue.
Risks and Watchpoints
- EU-GMP delay risk; beyond 3-4 months may require re-filing.
- Middle East disruption caused Q1 impact; currently normalizing.
- Regulatory MA timelines and CAPA acceptance remain key watchpoints.